STSanjaykumar Tambe

Sanjaykumar Tambe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sanjaykumar Tambe has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gestational Diabetes Awareness Is Low Among Low‐Income Pregnant Women Attending a Public Antenatal Clinic in Pune, India

    by Hannah Lee, Saanya Agarwal, Priyanka Raichur, Vedika Potphode, Mallika Alexander, Aditi Kole, Sanjaykumar Tambe, Shilpa Naik, Puja Chebrolu, Jyoti S. Mathad

    Objective: Gestational Diabetes (GDM) is increasingly common and associated with adverse outcomes, yet awareness remains low in many settings. We examined factors associated with GDM awareness among low and middle‐income pregnant women in India. Methods: Pregnant women were enrolled at a government hospital in Pune, India. Participants were asked if they had heard of diabetes and, if so, completed a 12‐item questionnaire assessing knowledge of GDM risk factors, testing and treatment, and consequences. Each correct response scored 1 point; scores of 0–4 were classified as poor awareness, 5–8 as fair, and 9–12 as good. Suboptimal awareness was defined as poor, fair, or no awareness. A multivariable logistic regression was used to assess risk factors for suboptimal awareness. Results: Among 368 women, median age was 25 years (IQR 22–29), gestational age 20.4 weeks (IQR 16.5–24.0), BMI 22.8 kg/m 2 (IQR 20–26.9); 33% ( n = 122) were primigravid, 31% ( n = 114) living with HIV, and 11% ( n = 41) had GDM. Among 326 (89%) of women who were aware of diabetes, median GDM awareness score was 9 (IQR 7–10). Overall, 197/368 (54%) women had suboptimal awareness. On multivariable analysis adjusting for residence, gravidity, and BMI, living with HIV (aOR 1.7, 95% CI 1.0–2.8, p = 0.04) and lower socioeconomic status (aOR 1.9, 95% CI 1.1, 3.2) were independently associated with odds of suboptimal GDM awareness. Conclusions: GDM awareness remains suboptimal among low‐income pregnant women in India, particularly among women with HIV. Targeted educational health interventions may improve awareness and reduce long‐term complications.

  • Open Access

    Dolutegravir Is Associated With Lower Odds of Gestational Diabetes Compared to Other Antiretroviral Therapy Regimens Among Pregnant Women in India: A Cross‐Sectional Analysis

    by Puja Chebrolu, Farheen Ahmed, Sanjaykumar Tambe, Mallika Alexander, Priyanka Raichur, Aditi Kole, Sonali Kante, Vandana Kulkarni, Nikhil Gupte, Ramesh Bhosale, et al.

    Introduction: In non‐pregnant adults living with HIV, dolutegravir is associated with weight gain and increased type 2 diabetes risk. In pregnancy, data on the effect of dolutegravir on gestational diabetes (GDM) risk is inconclusive. Data are particularly limited in Asian populations, where diabetes risk is especially high and not always associated with weight gain. We examined the association of dolutegravir with GDM among women living with HIV in India. Methods: We combined data from two cohorts of pregnant women living with HIV conducted at BJ Government Medical College in Pune, India—the PRACHITi study (2016−2019) and the PRAGATHi study (2023−present). Women were screened for GDM with the fasting 2‐h 75 g oral glucose tolerance test and diagnosed by World Health Organization criteria. Demographics, anthropometrics, antiretroviral therapy (ART), CD4 count and HIV viral load were collected at screening. Multivariate logistic regression was used to determine the association between current dolutegravir use and GDM. Results: Of 254 women living with HIV, 99.2% ( n = 252) were on ART, of whom 66.3% ( n = 167) were on dolutegravir‐, 22.6% ( n = 57) were on efavirenz‐ and 6.3% ( n = 16) were on protease inhibitor (PI)‐based ART. Overall, median CD4 count was 549.5 cells/mm 3 (IQR 401−753), and 82.2% ( n = 198) had undetectable viral load. Median body‐mass index (BMI) was 21.3 kg/m 2 (IQR 19.4−23.8). The prevalence of GDM was 11.8% ( N = 30). Among women on dolutegravir‐based ART, the prevalence was 10.8% ( N = 18); among women on efavirenz‐based ART, the prevalence was 12.3% ( N = 7), and the prevalence was 25% ( N = 4) among women on PI‐based ART. Compared to women not taking dolutegravir, women taking dolutegravir had similar age and BMI but greater weight gain from the second to the third trimester (3.7 vs. 2.9 kg, p p 2 , 95% CI 1.1−1.3) were also associated with GDM. Conclusions: Women on dolutegravir had lower odds of GDM compared to women taking other ART, despite greater weight gain. Ongoing studies are investigating the possible anti‐inflammatory mechanisms.